<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a previous report we showed decreased antibody-dependent cellular cytotoxicity (ADCC) activity of both leukemic and non-leukemic cells in human <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In our present study, ADCC against <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> target cells was evaluated in 13 patients with <z:e sem="disease" ids="C0026986" disease_type="Neoplastic Process" abbrv="MDS">preleukemic syndromes</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>ADCC was found to be significantly decreased in <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0001924'>sideroblastic anemia</z:hpo>, <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> and pure red cell <z:mpath ids='MPATH_58'>aplasia</z:mpath>, suggesting that impairment of immune defence capacity may precede the development of <z:hpo ids='HP_0001909'>leukemia</z:hpo> in man </plain></SENT>
</text></document>